Navigation Links
Biotel Announces Profitable Second Quarter Ended December 31, 2008
Date:2/12/2009

MINNEAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) announced results for its second quarter ended December 31, 2008, with net earnings of $289,000, or $0.10 per diluted share, on revenues of $3,186,000. This compares to net earnings of $206,000, or $0.07 per diluted share, on revenues of $2,859,000 for the second quarter of last year. For the six months ended December 31, 2008, Biotel had net earnings of $617,000, or $0.22 per diluted share, on revenues of $6,354,000. This compares to net earnings of $376,000, or $0.13 per diluted share, on revenues of $5,610.000 for the first six months of last year.

    Highlights for the second quarter are as follows:

    * Ninth consecutive profitable quarter
    * Net income up 40.3% year over year
    * Strong gross margin of 45.9%, versus 44.7% a year ago
    * Strong balance sheet with no long-term bank debt
    * Stockholders' equity of $5,320,000, up 22.8% year over year

"We are pleased with Biotel's revenue growth, margin improvement and overall performance in the second quarter," Biotel President and CEO Steve Springrose said. "Sales of the Braemar ER920W wireless arrhythmia monitor remained strong as one of our OEM partners continued ordering product for inventory stocking. We expect sales to this customer to diminish in the second half. Sales of Braemar Holter devices, event recorders, liposuction equipment and other medical devices remained solid. Having received FDA 510(k) approval of our Fusion platform of wireless ECG monitoring products, we are beginning shipments of an evaluation version of the product this quarter, followed by a planned limited clinical release and distribution of Fusion products in our fourth quarter. Biotel serves as a development partner to medical corporations seeking new devices and clinical research services."



                               3 months ended  3 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $3,186,000      $2,859,000         11.4%
    Net Income                     $289,000        $206,000         40.3%
    Earnings Per Share, Basic         $0.10           $0.08
    Earnings Per Share, Diluted       $0.10           $0.07



                               6 months ended  6 months ended
                                 December 31,    December 31,         %
                                     2008            2007           Change

    Revenues                     $6,354,000      $5,610,000         13.3%
    Net Income                     $617,000        $376,000         64.2%
    Earnings Per Share, Basic         $0.22           $0.14
    Earnings Per Share, Diluted       $0.22           $0.13

'/>"/>
SOURCE Biotel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biotel Announces Profitable Third Quarter Ended March 31, 2008
2. Biotel Announces Strong Results for the Second Quarter Ended December 31, 2007
3. Biotel Announces Strong Results for the First Quarter Ended September 30, 2007, FDA 510(k) Clearance for the Braemar ER900 Wireless Event Recorder
4. Biotel Announces Record Revenues and Strong Earnings for the Fourth Quarter and Year Ended June 30, 2007
5. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
6. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
7. Cogdell Spencer Announces Dorr as President of the Southeast Region
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
9. Terri Lynne Lokoff Child Care Foundation Announces Recipients of the 2009 Terri Lynne Lokoff/Childrens TYLENOL(R) National Child Care Teacher Awards(TM)
10. Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices
11. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: